Wockhardt on Thursday said it has received zero observations from the US health regulator after inspection of its bioequivalence centre at Aurangabad in Maharashtra. The United States Food and Drug Administration carried out the inspection on June 10 and 12, it said. This outcome would lead to approvals of abbreviated new drug applications (ANDAs) in the pipeline for which bioequivalence studies are being or will be done in the centre, Wockhardt said.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.